CV Therapeutics Ranexa review
FDA's Cardiovascular & Renal Drugs Advisory Committee will review CV Therapeutics Ranexa (ranolazine) for treatment of chronic stable angina at its Dec. 9 meeting. Review of the partial fatty acid oxidation inhibitor was previously scheduled for mid-September but was cancelled because FDA and the company did not have enough time to prepare for the meeting. The meeting will take place at the Hilton in Gaithersburg, Md. beginning at 8 a.m. [To 1watch a webcast of the meeting, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.